A Study to Evaluate the Relative Bioavailability and Food Effect of a VX-118 Tablet Formulation

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

April 2, 2024

Primary Completion Date

May 4, 2024

Study Completion Date

May 4, 2024

Conditions

Cystic Fibrosis

Interventions

DRUG

VX-118

Tablets and Suspension for Oral Administration

Trial Locations (1)

Celerion - Lincoln, Lincoln

All Listed Sponsors

lead

Vertex Pharmaceuticals Incorporated

INDUSTRY

NCT06312787 - A Study to Evaluate the Relative Bioavailability and Food Effect of a VX-118 Tablet Formulation | Biotech Hunter | Biotech Hunter